

Conclusion

gfrlafaboand Salt Lake VeteransværgijsDielpealitrale@eoten;tele8aEMeaalicinfen;Wanig98i®y

01-Nov-2022, Manuscript No. jdce-22-82500; 05-Nov-2022, PreQC No. jdce-22- 82500 (PQ); 12-Nov-2022, QC No. jdce-22-82500; 19-Nov-2022, Manuscript No. jdce-22-82500(R);

Acknowledgement

" • ,•

Con ict of Interest

H • 1•

- 1. Patrick R, Adrian F H, Scott DS, Faiez Z (2019) Heart failure drug treatment Lancet 393: 1034-1044.
- 2. Barry A B (2020) Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 17: 559-573.
- John JVM, Scott DS, Silvio EI, Lars K, Mikhail NK, et al. (2019) Dapaglifozin in patients with heart failure and reduced ejection fraction N Engl J Med 381: 1995-2008.
- Milton P, Stefan DA, Javed B, Gerasimos F, Stuart JP, et al. (2020) Cardiovascular and renal outcomes with empaglifozin in heart failure N Engl J Med 383: 1413-1424.

- William TA, JoAnn L, Piotr P, Piergiuseppe A, Javed B, et al. (2021) Empaglifozin in heart failure with a preserved ejection fraction N Engl J Med 385: 1451-1461.
- 6. Johann B (2021) Heart failure drug treatment: the fantastic four Eur Heart J 42: 681-683.
- Mahakpreet S, Anoop K (2018) Risks associated with SGLT2 inhibitors: an overview Curr Drug Saf 13: 84-91.
- Arsalan H, Muthiah V, Adebamike AO, Krishna KA, Andreas PK, et al. (2020) Antihyperglycemic therapies with expansions of US Food and Drug Administration indications to reduce cardiovascular events: Prescribing patterns within an academic medical center J Cardiovasc Pharmacol 76: 313-320.
- Rosario R, Stefani DD, Rafaello A, Cristina M (2012) Mitochondria as sensors and regulators of calcium signaling Nat Rev Mol Cell Biol 13: 566-578.
- Ajay NJ (2007) Surfex-Dock 2.1: Robust performance from ligand energetic modeling, ring fexibility, and knowledge-based search J Comput-Aided Mol Des 21: 281-306.